IBRX ImmunityBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1326110 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY121.2%
TTM net income YoY-218.3%
TTM EPS YoY-158.5%
Revenue 3-yr CAGR589.9%
Net income 3-yr CAGR—
Margins
Gross margin98.8%
Operating margin-150.2%
Net margin-607.8%
FCF margin-162.5%
EBITDA margin-141.1%
Returns
ROE—
ROA-196.7%
ROIC (approx.)—
Asset turnover0.32x
Leverage & solvency
Liabilities / assets288.0%
Debt / equity—
Current ratio4.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.26x
Accruals ratio-145.7%
Payout ratio—
Capex / revenue5.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $113.29M | $14.74M |
| Cost of revenue | $753,000 | $0 |
| Gross profit | $112.53M | $14.74M |
| R&D expense | — | $190.14M |
| SG&A expense | — | $168.78M |
| Operating income | -$256.03M | -$344.18M |
| Interest expense | $60.89M | $114.59M |
| Pretax income | -$351.61M | -$413.64M |
| Income tax | -$135,000 | $0 |
| Net income | -$351.40M | -$413.56M |
| EBITDA | -$240.50M | -$326.63M |
| EPS (basic) | -0.38 | -0.59 |
| EPS (diluted) | -0.38 | -0.62 |
| Weighted avg. shares (diluted) | 919.86M | 700.44M |
| Balance sheet | ||
| Cash & equivalents | $88.33M | $143.43M |
| Short-term investments | $154.48M | $6.38M |
| Receivables | $42.57M | $2.36M |
| Inventory | $910,000 | $8.27M |
| Current assets | $314.88M | $184.59M |
| PP&E, net | $114.26M | $137.09M |
| Goodwill | $910,000 | $910,000 |
| Intangibles | $12.99M | $14.53M |
| Total assets | $501.90M | $382.93M |
| Current liabilities | $61.75M | $54.94M |
| Short-term debt | $1.75M | $1.25M |
| Total liabilities | $1.00B | $871.06M |
| Shareholders' equity | -$500.47M | -$489.10M |
| Shares outstanding | 1.01B | 852.90M |
| Cash flow statement | ||
| Operating cash flow | -$304.94M | -$391.24M |
| Capital expenditure | $3.85M | $6.89M |
| Free cash flow | -$308.78M | -$398.12M |
| Investing cash flow | -$149.80M | -$12.25M |
| Financing cash flow | $400.24M | $281.63M |
| Depreciation & amortization | $15.53M | $17.55M |
| Stock-based compensation | $36.81M | $34.43M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.